Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CNX-2006 is a novel irreversible mutant-selective EGFR inhibitor with IC50 of < 20 nM, with very weak inhibition at wild-type EGFR.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 34.00 | |
2 mg | In stock | $ 48.00 | |
5 mg | In stock | $ 76.00 | |
10 mg | In stock | $ 128.00 | |
25 mg | In stock | $ 235.00 | |
50 mg | In stock | $ 425.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 92.00 |
Description | CNX-2006 is a novel irreversible mutant-selective EGFR inhibitor with IC50 of < 20 nM, with very weak inhibition at wild-type EGFR. |
Targets&IC50 | EGFR (mutant):<20 nM |
In vitro | CNX-2006 is a novel irreversible EGFR tyrosine kinase inhibitor, specifically inhibits activating mutations of EGFR as well as the T790M mutation while having very weak inhibition at wild-type EGFR. In in vitro modeling of acquired resistance, continuous CNX-2006 treatment on drug-sensitive EGFR mutant cells leads to resistance more slowly than erlotinib. Dose escalation with CNX-2006 leads to differential effects in different lines, but does not select for T790M-mediated resistance. [1]CNX-2006 resistent cells shows increased expression of EMT markers and MMP9.[2] |
In vivo | CNX-2006 is effective in H1975 (EGFR L858R/T790M) xenograft model. [1] [2] |
Kinase Assay | Growth inhibition assays: Human EGFR mutant lung adenocarcinoma cell lines are treated with drugs in standard growth inhibition assays. |
Cell Research | Cells with endogenous or transiently transfected mutant EGFRs (293 cells) are treated with inhibitors for 6 hours and then corresponding lysates are extracted and analyzed by immunoblotting.(Only for Reference) |
Animal Research | Animal Models: Nude miceFormulation: 5% DMSO:15% Solutol HS15 in PBSDosages: 25 mg/kgAdministration: i.p. |
Synonyms | CNX 2006, CNX2006 |
Molecular Weight | 545.53 |
Formula | C26H27F4N7O2 |
CAS No. | 1375465-09-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMF: soluble
DMSO: 91 mg/mL(166.8 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CNX-2006 1375465-09-0 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR CNX 2006 HER1 inhibit Epidermal growth factor receptor ErbB-1 CNX2006 Inhibitor inhibitor